论文部分内容阅读
临床应用利福平出现肝毒性的问题,已逐渐引起重视。肝毒性的发生率为1.8～35%,报道颇不一致,但多数在10%左右。肝损害程度文献记载也不尽相同,过去多认为较轻微,虽也有严重肝毒性报道,但未引起重视。近年来这种报道日渐增多,如孙氏等报告26例利福平肝毒性病人中,有5例(19.2%)因GPT持续升高,黄疸及明显的临床症状而停药;刘氏报告25例肝毒性中有1例死亡;Decroix等报告173例用利福平的病人中转氨酶升高者40例(23%),
Clinical application of rifampin hepatotoxicity has gradually attracted the attention. The incidence of hepatotoxicity is 1.8 to 35%, reports quite inconsistent, but most of the 10%. The extent of liver damage documented are not the same, in the past considered more minor, although there are serious reports of liver toxicity, but did not attract attention. In recent years, such reports have been increasing, such as Sun and other reports of 26 cases of rifampicin liver toxicity patients, 5 patients (19.2%) due to continued GPT rise, jaundice and obvious clinical symptoms and withdrawal; Liu reported 25 One patient died of hepatotoxicity; Decroix et al. Reported that 40 (23%) of the 173 patients with rifampicin had elevated transaminases,